Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial - Concepedia

Concepedia

Publication | Open Access

Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial

DOI Full Paper Access

211

Citations

10

References

2019

Year

Hiddo J.L. Heerspink, Bergur V. Stefánsson, Glenn M. Chertow, Ricardo Correa‐Rotter, Tom Greene, Fan Fan Hou, Magnus Lindberg, John J.V. McMurray, Peter Rossing, Roberto D. Toto,

Nephrology Dialysis Transplantation

Abstract

DAPA-CKD will determine whether the SGLT2 inhibitor dapagliflozin, added to guideline-recommended therapies, safely reduces the rate of renal and cardiovascular events in patients across multiple CKD stages with and without diabetes.

References

	Year	Citations

Page 1